Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
Marsh & McLennan Companies, Inc.Trade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Marsh & McLennan Companies, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Marsh & McLennan Companies, Inc. trades at $191.32 (market cap $91.27B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 18× ACADIA Pharmaceuticals Inc.'s market cap, and Marsh & McLennan Companies, Inc. pays a 2.07% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.

ACADMRSH
Market Cap
$5.07B$91.27B
Sector
HealthFinancials
52-Week High
$29.41$211.21
52-Week Low
$20.06$157.32
Enterprise Value
$4.19B$111.95B
Dividend Yield
2.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.

Marsh & McLennan Companies, Inc.

Marsh & McLennan (MRSH) trades at $188.81, down 1.04% today, but maintains a bullish technical trend with strong fundamentals. The company reported Q2 2026 EPS of $2.96, beating estimates, and has consistently exceeded earnings expectations. Revenue growth remains solid at 6% in Q2 2026, driven by risk and consulting services. Recent acquisitions, like the planned purchase of Accel Holdings, aim to expand its Midwest insurance reach.

The outlook is positive with a consensus price target of $202.89, suggesting 7.5% upside. Risks include margin pressure from rising expenses and soft P&C pricing. Analyst sentiment is mixed with 30.3% buy ratings but 66.7% hold, indicating cautious optimism. Institutional activity shows new positions by Ashton Thomas Securities and Bank of Nova Scotia, supporting long-term growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Marsh & McLennan Companies, Inc.

Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).

Read more on MRSH